In Brief: Cardiac Pathways
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pathways: Receives investigational device exemption from FDA for its Arrythmia Mapping System cardiac ablation product for the treatment of tachyarrhythmias in the right atrium. Trials of the system, which utilizes Cardiac Pathways' 64-electrode Mercator "basket" mapping catheter, will take place at five U.S. sites and compare the AMS to other "commercially available mapping catheters." The Sunnyvale, California firm received IDE approval in February for use of the system in the left ventricle ("The Gray Sheet" Feb. 12, In Brief)...